[go: up one dir, main page]

BR0315644A - Piperazinil e diazapanil benzamidas e benzotioamidas - Google Patents

Piperazinil e diazapanil benzamidas e benzotioamidas

Info

Publication number
BR0315644A
BR0315644A BR0315644-3A BR0315644A BR0315644A BR 0315644 A BR0315644 A BR 0315644A BR 0315644 A BR0315644 A BR 0315644A BR 0315644 A BR0315644 A BR 0315644A
Authority
BR
Brazil
Prior art keywords
piperazinyl
benzothioamides
benzamides
diazapanyl
diazapanyl benzamides
Prior art date
Application number
BR0315644-3A
Other languages
English (en)
Other versions
BRPI0315644B8 (pt
BRPI0315644B1 (pt
Inventor
Richard L Apodaca
Jill A Jablonowski
Kiev S Ly
Chandravadan R Shah
Devin M Swanson
Wei Xiao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0315644A publication Critical patent/BR0315644A/pt
Publication of BRPI0315644B1 publication Critical patent/BRPI0315644B1/pt
Publication of BRPI0315644B8 publication Critical patent/BRPI0315644B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0465—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K51/047—Benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)

Abstract

"PIPERAZINIL E DIAZAPANIL BENZAMIDAS E BENZOTIOAMIDAS". Piperazinil e diazepanil benzamidas e benzotioamidas substituídas de fórmula (I), composições contendo as mesmas, e métodos para fabricação e uso das mesmas no tratamento de condições mediadas por histamina.
BRPI0315644A 2002-10-23 2003-10-21 compostos de piperazinil e diazapanil benzamidas e benzotioamidas, suas composições e respectivos usos BRPI0315644B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42049502P 2002-10-23 2002-10-23
PCT/US2003/033343 WO2004037801A1 (en) 2002-10-23 2003-10-21 Piperazinyl and diazapanyl benzamides and benzthioamides

Publications (3)

Publication Number Publication Date
BR0315644A true BR0315644A (pt) 2005-08-30
BRPI0315644B1 BRPI0315644B1 (pt) 2018-11-13
BRPI0315644B8 BRPI0315644B8 (pt) 2021-05-25

Family

ID=32176579

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0315644A BRPI0315644B8 (pt) 2002-10-23 2003-10-21 compostos de piperazinil e diazapanil benzamidas e benzotioamidas, suas composições e respectivos usos

Country Status (32)

Country Link
US (2) US7414047B2 (pt)
EP (1) EP1558595B1 (pt)
JP (1) JP4596918B2 (pt)
KR (1) KR101067732B1 (pt)
CN (1) CN100558718C (pt)
AR (1) AR041697A1 (pt)
AT (1) ATE449766T1 (pt)
AU (1) AU2003301552B2 (pt)
BR (1) BRPI0315644B8 (pt)
CA (1) CA2504269C (pt)
CR (1) CR7807A (pt)
CY (1) CY1109924T1 (pt)
DE (1) DE60330269D1 (pt)
DK (1) DK1558595T3 (pt)
EA (1) EA009860B1 (pt)
EG (1) EG25097A (pt)
ES (1) ES2335584T3 (pt)
HR (1) HRP20050352B1 (pt)
IL (1) IL168207A (pt)
ME (1) ME00334B (pt)
MX (2) MXPA05004384A (pt)
MY (1) MY140886A (pt)
NO (1) NO330741B1 (pt)
NZ (2) NZ576432A (pt)
PL (1) PL215454B1 (pt)
PT (1) PT1558595E (pt)
RS (1) RS51681B (pt)
SI (1) SI1558595T1 (pt)
TW (1) TWI352594B (pt)
UA (1) UA80573C2 (pt)
WO (1) WO2004037801A1 (pt)
ZA (1) ZA200504067B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05004384A (es) 2002-10-23 2005-10-18 Johnson & Johnson Piperacinil y diacepanil benzamidas y benztioamidas.
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
ATE490959T1 (de) * 2004-03-31 2010-12-15 Janssen Pharmaceutica Nv Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors
CA2561791A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds
PT1948607E (pt) * 2005-09-16 2010-06-02 Janssen Pharmaceutica Nv Ciclopropilaminas como moduladores do receptor h3 de histamina
BRPI0618076A2 (pt) * 2005-10-31 2011-08-16 Janssen Pharmaceutica Nv processos para a preparação de derivados de ciclopropil-amida
WO2007053427A2 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
US7795426B2 (en) 2005-10-31 2010-09-14 Janssen Pharmaceutica Nv Processes for the preparation of cyclopropyl-amide derivatives
WO2007055418A1 (ja) * 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
JP5285603B2 (ja) * 2006-05-30 2013-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体のモジュレーターとしての置換ピリジルアミド化合物
NZ611323A (en) 2006-06-23 2014-10-31 Abbvie Bahamas Ltd Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US20080045507A1 (en) * 2006-06-29 2008-02-21 Allison Brett D Substituted benzamide modulators of the histamine h3 receptor
BRPI0721088B8 (pt) 2006-12-14 2021-05-25 Janssen Pharmaceutica Nv processo para a preparação de derivados de piperazinil e diazepanil benzamida
ATE554081T1 (de) 2007-09-06 2012-05-15 Glaxo Group Ltd Piperazinderivate mit affinität zum histamin-h3- rezeptor
AR068509A1 (es) * 2007-09-19 2009-11-18 Jerini Ag Antagosnistas del receptor de bradiquinina b1
EP2222664B1 (en) 2007-11-20 2014-10-29 Janssen Pharmaceutica, N.V. Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
MX349489B (es) * 2009-03-18 2017-07-31 Janssen Pharmaceutica Nv Proceso para la preparación de moduladores del receptor h3 de histamina.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
RU2700595C1 (ru) * 2019-07-30 2019-09-18 Общество с ограниченной ответственностью "Кью Эм Фарма" Производное 3,6,9-триазатрициклотетрадекана и его применение для лечения депрессии
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714179A (en) 1970-09-08 1973-01-30 Searle & Co 1-alkyl-2-furfurylthioimidazoles and congeners
US3886160A (en) 1972-09-28 1975-05-27 Searle & Co 2-(2-Methyl-5-nitro-1-imidazolyl) ethyl-2-thiopseudoureas
EP0186817B1 (en) * 1984-12-10 1989-08-02 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
JP2813747B2 (ja) 1989-05-22 1998-10-22 富士写真フイルム株式会社 画像形成法
US5030644A (en) 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5492891A (en) 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
US5569659A (en) 1991-09-11 1996-10-29 Mcneilab, Inc. 4-arylpiperazines and 4-arylpiperidines
US5217986A (en) 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
EP0794779A4 (en) 1994-12-22 1998-04-29 Smithkline Beecham Corp FIBRINOGENIC RECEPTOR ANTAGONISTS
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JPH09294056A (ja) * 1996-04-25 1997-11-11 Mitsubishi Electric Corp 半導体集積回路
JPH1059954A (ja) 1996-08-14 1998-03-03 Takeda Chem Ind Ltd 環状アミン誘導体およびそれを含んでなる医薬
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
AU9650398A (en) 1997-11-07 1999-05-31 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
DE60126785T2 (de) 2000-08-08 2007-10-25 Ortho-Mcneil Pharmaceutical, Inc. Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
CN1468227A (zh) 2000-08-08 2004-01-14 ����-������ҩƷ��˾ 非咪唑芳氧基烷基胺
WO2002024695A2 (en) 2000-09-22 2002-03-28 Ortho Mcneil Pharmaceutical, Inc. Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
EP1379493A2 (en) 2001-03-23 2004-01-14 Eli Lilly and Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
EP1434765B1 (en) 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
JP4619655B2 (ja) 2001-09-14 2011-01-26 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
MXPA04005562A (es) 2001-12-10 2005-04-19 Johnson & Johnson Fenilalquinos.
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
DE10201240A1 (de) * 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
MXPA04007416A (es) 2002-02-01 2004-10-11 Novo Nordisk As Amidas de azetidinas, pirrolidinas, piperidinas y azepanos sustituidos como aminoalquilo.
MXPA05004384A (es) 2002-10-23 2005-10-18 Johnson & Johnson Piperacinil y diacepanil benzamidas y benztioamidas.
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
DE60330269D1 (de) 2010-01-07
JP2006510609A (ja) 2006-03-30
JP4596918B2 (ja) 2010-12-15
PT1558595E (pt) 2010-01-15
AU2003301552B2 (en) 2010-04-22
ME00334B (me) 2011-05-10
CA2504269A1 (en) 2004-05-06
ZA200504067B (en) 2006-08-30
DK1558595T3 (da) 2010-03-29
ES2335584T3 (es) 2010-03-30
MXPA05004384A (es) 2005-10-18
SI1558595T1 (sl) 2010-03-31
EG25097A (en) 2011-08-17
CA2504269C (en) 2012-01-17
MEP49508A (en) 2011-02-10
PL376324A1 (en) 2005-12-27
HRP20050352B1 (hr) 2013-09-30
US20080056991A1 (en) 2008-03-06
KR20050055775A (ko) 2005-06-13
NZ576432A (en) 2010-06-25
NO330741B1 (no) 2011-06-27
EP1558595B1 (en) 2009-11-25
AU2003301552A1 (en) 2004-05-13
BRPI0315644B8 (pt) 2021-05-25
US20040110746A1 (en) 2004-06-10
KR101067732B1 (ko) 2011-09-28
CR7807A (es) 2008-09-10
HK1086827A1 (zh) 2006-09-29
EP1558595A1 (en) 2005-08-03
RS20050317A (sr) 2007-09-21
CN1729180A (zh) 2006-02-01
IL168207A (en) 2011-07-31
AR041697A1 (es) 2005-05-26
TW200418476A (en) 2004-10-01
RS51681B (sr) 2011-10-31
MX339074B (es) 2016-05-09
WO2004037801A1 (en) 2004-05-06
ATE449766T1 (de) 2009-12-15
NO20052278L (no) 2005-06-06
EA200500528A1 (ru) 2005-10-27
EA009860B1 (ru) 2008-04-28
HRP20050352A2 (en) 2006-06-30
PL215454B1 (pl) 2013-12-31
US7414047B2 (en) 2008-08-19
MY140886A (en) 2010-01-29
CN100558718C (zh) 2009-11-11
NZ539595A (en) 2008-02-29
CY1109924T1 (el) 2014-09-10
BRPI0315644B1 (pt) 2018-11-13
UA80573C2 (en) 2007-10-10
TWI352594B (en) 2011-11-21

Similar Documents

Publication Publication Date Title
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
IS6658A (is) Ný efnasambönd
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
BR0215405A (pt) Composições e processos de uso de collajolie
DE60112974D1 (en) Carbolinderivate
SE0101387D0 (sv) Novel compounds
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
PT1263725E (pt) Novos compostos
SE0301653D0 (sv) Novel compounds
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
BR0306922A (pt) N-pirazinil-fenilsulfonamidas e seu uso no tratamento de doenças mediadas por quimocina
SE9802729D0 (sv) Novel Compounds
SE0302139D0 (sv) Novel compounds
DE60216233D1 (en) Carbolinderivate
ATE304523T1 (de) Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1- naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
ATE297903T1 (de) Substituierte phenyluracile
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE60325377D1 (de) Motilidverbindungen
BRPI0411837A (pt) pirazolopirimidinas
SE9903290D0 (sv) Novel compounds
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
PT1204659E (pt) Benzofuranos serotoninergicos
SE0102641D0 (sv) Novel compounds
EA200400661A1 (ru) Фенилалкины

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTICA N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2745 DE 15-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.